Table 1.
Clinical trials evaluating ALK inhibitors in neuroblastoma.
| Trial Identifier | Sponsor | Phase | Disease Eligibility | Study Drug(s) | Start Date | References |
|---|---|---|---|---|---|---|
| NCT00939770 | COG | I/II | r/r solid tumours and ALCL | crizotinib | September 2009 | [112,113,114] |
| NCT01121588 | Pfizer | I | all ALK-positive tumours except NSCLC; ≥15 years | crizotinib | March 2011 | [115] |
| NCT01606878 | COG | I | r/r solid tumours and ALCL | crizotinib + chemotherapy | March 2013 | [116] |
| NCT01742286 | Novartis | I | all r/r ALK-positive tumours | ceritinib | August 2013 | [117] |
| NCT02650401 | Ignyta | I/Ib | r/r solid tumours | entrectinib | December 2015 | [118] |
| NCT02780128 | Y.P. Mossé | I | r/r NB | ceritinib + ribociclib | July 2016 | [119] |
| NCT03213652 | NCI | II | r/r ALK/ROS1-positive solid tumours, NHL, histiocytic disorders | ensartinib | July 2017 | [120,121] |
| NCT03107988 | NANT Consortium | I | high-risk NB | lorlatinib +/− chemotherapy | September 2017 | [122] |
| NCT03126916 | COG | III | high-risk NB and ganglioneuroblastoma | crizotinib + standard therapy | December 2017 | [123] |
ALCL: anaplastic large cell lymphoma; COG: Children’s Oncology Group; NANT: New Approaches to Neuroblastoma Therapy; NB: neuroblastoma; NCI: National Cancer Institute; NHL: non-Hodgkin’s lymphoma; r/r: relapsed or refractory.